MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$30,526K
EPS
-$0.43
Unit: Thousand (K) dollars

Income Statement
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Research and development
22,195 22,255 26,755* 22,575
General and administrative
9,773 8,930 6,569* 7,372
Total operating expenses
31,968 31,185 33,324 29,947
Loss from operations
-31,968 -31,185 -33,324* -29,947
Interest income
2,663 2,740 2,727* 2,233
Interest expense
745 732 720* 758
Loss on extinguishment of debt
NaN -488 0* NaN
Other expenses, net
-177 -87 271* -280
Total other income, net
1,741 1,433 2,278* 1,195
Net loss before income taxes
-30,227 -29,752 -31,046* -28,752
Provision for income taxes
0 0 -717* 239
Net loss
-30,227 -29,752 -30,329* -28,991
Unrealized loss (gain) on available-for-sale investments
-299 46 1,251* -240
Total comprehensive loss
-30,526 -29,706 -29,078 -29,231
Basic EPS
-0.43 0.44 -0.569 0.57
Diluted EPS
-0.43 0.44 -0.569 0.57
Basic Average Shares
69,724,761 67,263,234 51,141,247 51,097,711
Diluted Average Shares
69,724,761 67,263,234 51,141,247 51,097,711
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Total comprehensiveloss-$30,526K Net loss-$30,227K Unrealized loss (gain) onavailable-for-sale investments-$299K Interest income$2,663K Net loss beforeincome taxes-$30,227K Total other income,net$1,741K Interest expense$745K Other expenses, net-$177K Loss from operations-$31,968K Total operatingexpenses$31,968K Research and development$22,195K General andadministrative$9,773K

enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Inc. (ENGN)